AUPH - Aurinia Pharmaceuticals Inc.
| Previous Close | 6.27 |
| Open | 6.17 |
| Bid | 6.28 x 800 |
| Ask | 6.29 x 1100 |
| Day's Range | 6.12 - 6.29 |
| 52 Week Range | 5.06 - 7.85 |
| Volume | 128,084 |
| Avg. Volume | 574,506 |
| Market Cap | 576.696M |
| Beta (3Y Monthly) | 0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Business Wire•5 days ago
ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts
ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today filed an investor presentation on SEDAR in connection with the Corporation’s upcoming Annual General Meeting of Shareholders to be held on Wednesday, June 26, 2019. The investor presentation is also available at www.AHealthierAurinia.com.
- Business Wire•7 days ago
ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
ILJIN SNT Co., Ltd. (“ILJIN”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or the “Corporation”), highlighting the governance failures and director conflicts under the current board of directors, correcting misleading information disseminated to shareholders by Aurinia on June 7, 2019 and urging shareholders to vote their GREEN proxy or GREEN VIF to strengthen the board. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.
- Business Wire•10 days ago
Aurinia Issues Letter to Shareholders
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today sent a letter to shareholders in connection with the Company’s upcoming Annual General Meeting of Shareholders (“AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.
- Business Wire•13 days ago
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the fol
- Business Wire•14 days ago
Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders
ILJIN SNT Co., Ltd. (“ILJIN”) today announced that it has filed an information circular (the "Circular") and letter to shareholders in connection with the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”) to be held on Wednesday, June 26, 2019. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.
- Business Wire•17 days ago
Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Circular. Aurinia plans to host its upcoming Annual General Meeting of Shareholders (“AGM”) at 10:00 a.m. MT on Wednesday, June 26, 2019, at the Westin Calgary, 320 4th Ave SW in Calgary, Alberta. The Company also issued a letter to shareholders in response to the receipt of an advance notice of nominees from a minority shareholder who intends to nominate four alternate directors.
- Business Wire•last month
Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT in New York, NY.
- Zacks•last month
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Aurinia: 1Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. The results matched Wall Street expectations. The ...
- Business Wire•last month
Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights
- Conference call and webcast to be hosted today at 4:30pm EDT -
- Business Wire•last month
Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis
In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. a late clinical-stage biopharmaceutical company with
- Zacks•2 months ago
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board. “On behalf of the entire organization, it is a pleasure to welcome Daniel onto Aurinia’s Board of Directors.
- Business Wire•2 months ago
Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.
- American City Business Journals•2 months ago
Former MedImmune president Greenleaf tapped to lead Canadian biotech
Peter Greenleaf was most recently CEO of Baltimore-based Cerecor Inc., a rare disease therapy company that topped the BBJ's list of fastest-growing public companies last year.
- Business Wire•2 months ago
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors.
- Zacks•2 months ago
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Motley Fool•3 months agoAurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
AUPH earnings call for the period ending December 31, 2018.
- Associated Press•3 months ago
Aurinia: 4Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...
- Business Wire•3 months ago
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.
- ACCESSWIRE•3 months ago
Aurinia Pharmaceuticals Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 19, 2019 at ...
- Business Wire•3 months ago
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease.
- Zacks•3 months ago
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
Aurinia Pharmaceuticals Inc. today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.
